- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01289717
Proteogenomic Biomarker Panels in a Serial Blood & Urine Monitoring Study of Kidney Transplant Recipients (PROGENI-KI)
Discovery and Validation of Proteogenomic Biomarker Panels in a Prospective Serial Blood & Urine Monitoring Study of Kidney Transplant Recipients - Transplant Proteogenomics
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Kidney transplantation is a good treatment option for people with kidney disease. However, there is still much to learn about how to best care for the transplanted kidney and keep it working for a long time. One field of interest is how one's cellular make-up might affect the body's immune response (body's natural defense system to illness and foreign things) to a kidney transplant. Cellular tests, like gene expression, help doctors to study a person's cellular traits. Gene expression is when information found in one's DNA is translated into RNA and eventually proteins. These components are present in each of the body's cells. In this study, researchers are trying to learn if certain changes in the RNA and proteins found in blood, urine, or transplant biopsy tissue can detect rejection before injury can occur or become too severe. The blood and urine tests will look for patterns in one's DNA (called genetic markers).
This study will follow subjects for 2 years after transplant. There will be a total of 12 study visits with additional study visits if rejection occurs. The study requires additional samples of blood, urine, and tissue to be collected during routine clinical visits and biopsies (a procedure to remove and examine a small piece of kidney tissue).
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
Arizona
-
Phoenix, Arizona, États-Unis, 85054
- Mayo Clinic, Division of Nephrology
-
-
California
-
La Jolla, California, États-Unis, 92037
- The Scripps Research Institute, Scripps Center for Organ and Cell Transplantation,
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60611
- Northwestern University, Feinberg School of Medicine, Division of Organ Transplantation
-
-
Ohio
-
Cleveland, Ohio, États-Unis, 44195
- The Cleveland Clinic
-
-
South Carolina
-
Charleston, South Carolina, États-Unis, 29425
- Medical University of South Carolina, Division of Transplant
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Subjects undergoing primary or subsequent deceased-donor or living donor kidney transplantation
- Subject and/or parent guardian must be able to understand and provide informed consent
- Female subjects of childbearing potential must have a negative pregnancy test within 6 weeks of study entry.
Exclusion Criteria:
- Need for combined organ transplantation with an extra-renal organ and/or islet
- Recipient of previous non-renal solid organ and/or islet cell transplantation
- Infection with hepatitis C virus (HCV) or human immunodeficiency virus (HIV)
- Inability or unwillingness of a participant to give written informed consent or comply with study protocol
- Any condition that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: Cohorte
- Perspectives temporelles: Éventuel
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
Incidence of Biopsy Proven Acute Rejection (AR)-Clinical and Sub-Clinical), Chronic Allograft Nephropathy/Interstitial Fibrosis and Tubular Atrophy (CAN/IFTA), and Normal Renal Biopsy with Stable, Good Kidney Function
Délai: 12 and 24 months
|
12 and 24 months
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
Incidence of Death
Délai: Baseline to month 24
|
Baseline to month 24
|
Incidence of Graft Loss
Délai: Baseline to month 24
|
Baseline to month 24
|
Incidence of Opportunistic infections
Délai: Baseline to month 24
|
Baseline to month 24
|
Incidence of BKV, CMV, and EBV Infection
Délai: Baseline to month 24
|
Baseline to month 24
|
Incidence of Treated Urinary Tract Infection
Délai: Baseline to month 24
|
Baseline to month 24
|
Incidence of Malignancy
Délai: Baseline to month 24
|
Baseline to month 24
|
Changes that Occur in Blood, Urine, and Kidney Tissue Gene Expression Signature
Délai: Month 1 to month 24
|
Month 1 to month 24
|
Changes in Plasma Protein Expression Profile
Délai: Month 1 to month 24
|
Month 1 to month 24
|
Changes in Urine Protein Expression Profile
Délai: Month 1 to month 24
|
Month 1 to month 24
|
Changes in Blood MicroRNA Expression Profile
Délai: Month 1 to month 24
|
Month 1 to month 24
|
Evolution of Gene and Protein Expression Profiles During Response to Therapy for AR
Délai: Month 1 to month 24
|
Month 1 to month 24
|
Evolution of Gene and Protein Expression Profiles During Progression or Regression of CAN/IFTA on Protocol Biopsies
Délai: Month 1 to month 24
|
Month 1 to month 24
|
Collaborateurs et enquêteurs
Collaborateurs
Les enquêteurs
- Chercheur principal: Michael Abecassis, MD, MBA, Northwestern University
- Chaise d'étude: John J Friedewald, MD, Northwestern University
Publications et liens utiles
Publications générales
- Kurian SM, Heilman R, Mondala TS, Nakorchevsky A, Hewel JA, Campbell D, Robison EH, Wang L, Lin W, Gaber L, Solez K, Shidban H, Mendez R, Schaffer RL, Fisher JS, Flechner SM, Head SR, Horvath S, Yates JR, Marsh CL, Salomon DR. Biomarkers for early and late stage chronic allograft nephropathy by proteogenomic profiling of peripheral blood. PLoS One. 2009 Jul 10;4(7):e6212. doi: 10.1371/journal.pone.0006212.
- Brouard S, Mansfield E, Braud C, Li L, Giral M, Hsieh SC, Baeten D, Zhang M, Ashton-Chess J, Braudeau C, Hsieh F, Dupont A, Pallier A, Moreau A, Louis S, Ruiz C, Salvatierra O, Soulillou JP, Sarwal M. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15448-53. doi: 10.1073/pnas.0705834104. Epub 2007 Sep 14.
- Mas VR, Mas LA, Archer KJ, Yanek K, King AL, Gibney EM, Cotterell A, Fisher RA, Posner M, Maluf DG. Evaluation of gene panel mRNAs in urine samples of kidney transplant recipients as a non-invasive tool of graft function. Mol Med. 2007 May-Jun;13(5-6):315-24. doi: 10.2119/2007-00017.Mas.
- Muthukumar T, Dadhania D, Ding R, Snopkowski C, Naqvi R, Lee JB, Hartono C, Li B, Sharma VK, Seshan SV, Kapur S, Hancock WW, Schwartz JE, Suthanthiran M. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med. 2005 Dec 1;353(22):2342-51. doi: 10.1056/NEJMoa051907.
- Veronese F, Rotman S, Smith RN, Pelle TD, Farrell ML, Kawai T, Benedict Cosimi A, Colvin RB. Pathological and clinical correlates of FOXP3+ cells in renal allografts during acute rejection. Am J Transplant. 2007 Apr;7(4):914-22. doi: 10.1111/j.1600-6143.2006.01704.x. Epub 2007 Feb 7.
- Kurian SM, Williams AN, Gelbart T, Campbell D, Mondala TS, Head SR, Horvath S, Gaber L, Thompson R, Whisenant T, Lin W, Langfelder P, Robison EH, Schaffer RL, Fisher JS, Friedewald J, Flechner SM, Chan LK, Wiseman AC, Shidban H, Mendez R, Heilman R, Abecassis MM, Marsh CL, Salomon DR. Molecular classifiers for acute kidney transplant rejection in peripheral blood by whole genome gene expression profiling. Am J Transplant. 2014 May;14(5):1164-72. doi: 10.1111/ajt.12671. Epub 2014 Apr 11.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- DAIT CTOT-08
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Transplantation rénale
-
Abramson Cancer Center of the University of PennsylvaniaRetiréPatients cancéreux subissant une greffe de cellules souches (RCT of ACP for Transplant)